Roiver Score™ for
RNACCartesian Therapeutics, Inc. Common Stock
Based on the annual report for the fiscal year ended December 31, 2025.
Cartesian Therapeutics, Inc. Common Stock (RNAC) scores 0/100 (Weak) on the Roiver Score, a transparent quality composite, based on its annual report for the fiscal year ended December 31, 2025. The score measures business quality, not timing — it's a signal, not a recommendation.
No black box
Roiver Score is a transparent 0–100 quality composite. Five components, each scored 0–20. If one can't be measured from a company's filings, the score is scaled from the ones that can (at least three are required). Banks, insurers and REITs are scored on measures suited to them. Inspired by Piotroski's F-Score, Altman's Z-Score, and the Buffett/Munger framework on quality compounders at fair prices. Read the full methodology →
Frequently asked about RNAC
What is RNAC's Roiver Score?
Cartesian Therapeutics, Inc. Common Stock scores 0 out of 100 (Weak). Based on the annual report for the fiscal year ended December 31, 2025.
How is the Roiver Score for RNAC calculated?
It combines profitability, capital structure, cash quality, valuation and stability into a transparent 0–100 composite. Five components, each scored 0–20. If one can't be measured from a company's filings, the score is scaled from the ones that can (at least three are required). The full methodology is published.
Is RNAC a good quality stock?
On quality, RNAC rates "Weak" (0/100). Quality is one input to a decision, not a buy/sell call.
Embed on your site
Drop this iframe into a Substack, blog post, or notion page. Updates automatically as fundamentals change.
<iframe src="https://roiver.com/embed/score/RNAC" width="640" height="280" frameborder="0" style="border:0;border-radius:16px;overflow:hidden" loading="lazy"></iframe>
Get RNAC's Score in your inbox
A free weekly digest of quality scores and what changed. No account needed.
Educational use only. Roiver Score is a quality signal, not a recommendation.